Kirjojen hintavertailu. Mukana 12 362 430 kirjaa ja 12 kauppaa.
Kirja.info

Kirjahaku

Etsi kirjoja tekijän nimen, kirjan nimen tai ISBN:n perusteella.

26 tulosta hakusanalla "Myelodysplastic Syndromes"

100 Questions & Answers About Myelodysplastic Syndromes

100 Questions & Answers About Myelodysplastic Syndromes

Jason Gotlib; Lenn Fechter

Jones and Bartlett Publishers, Inc
2015
nidottu
Newly revised and updated, Questions amp Answers About Myelodysplastic Syndromes provides authoritative and practical answers to the most common questions asked by patients and their loved ones. What is myelodysplastic syndromes (MDS)? What causes MDS? Is MDS hereditary, and will I give it to my children?Written by experts in the field, and with commentary from actual patients, this guide is the only text available to provide both the doctor's and patient's views. Questions amp Answers About Myelodysplastic Syndromes is an invaluable resource for anyone struggling with the medical, physical, and emotional turmoil of this disease.
Vertaile hintoja
Recent Developments in Myelodysplastic Syndromes

Recent Developments in Myelodysplastic Syndromes

IntechOpen
2019
sidottu
This book deals with the rapid progress in the area of myelodysplastic syndromes (MDS). MDS are a group of age-associated heterogeneous malignant bone marrow stem cell disorders. MDS are characterized by ineffective hematopoiesis, which leads to refractory cytopenias and to clonal instability. Patients with MDS have myeloid dysplasia, intramedullary apoptosis and an increased risk of transformation to acute myeloid leukemia (AML). The use of next generation sequencing has allowed for the identification of molecular mutations in several genes in about 90% of MDS patients. Several mutations will likely be incorporated into future prognostic scoring systems for MDS. About 50% of MDS cases are characterized by the presence of cytogenetic abnormalities. The correct morphological and cytogenetic analysis interpretation plays an important role in diagnosis and prognosis of these disorders. Cell death and an inflammatory gene signature are associated with MDS. Better understanding of the genetic and molecular mechanisms of MDS pathogenesis provides an opportunity for new treatment strategies to be developed. Promising novel therapies targeting pathophysiological mechanisms of MDS are being studied but the drugs currently used in MDS therapy remain limited. The only curative therapy for MDS is allogeneic hematopoietic stem cell transplantation. Recent advances in strategies to minimize transplant-related toxicity make this treatment possible for more MDS patients who are sufficiently fit.
Vertaile hintoja
Clinician’s Manual on Myelodysplastic Syndromes

Clinician’s Manual on Myelodysplastic Syndromes

Alan List

Current Medicine Group
2011
nidottu
An overview of diagnosis and current management of myelodysplastic syndromes. - Reviews the performance of the pharmacological treatments currently available and analyses the potential for new treatments - High quality clinical photos and figures to enhance descriptions and improve reader comprehension - Useful reference text for healthcare professionals needing to know more about myelodysplastic syndromes
Vertaile hintoja
Diagnosis and Management of Myelodysplastic Syndromes

Diagnosis and Management of Myelodysplastic Syndromes

Springer Nature Switzerland AG
2020
sidottu
Myelodysplastic syndromes (MDS) are a group of clonal disorders characterized by pancytopenias and the risk of progression to acute myeloid leukemia. The diagnosis of MDS can be challenging, while the outcomes of MDS patients vary widely. This book provides a concise yet comprehensive overview of MDS.The book begins by reviewing the diagnostic workup of MDS, with a specific focus on the 2016 WHO criteria for MDS diagnosis, and the biology and pathophysiology of the disease. The text then presents the molecular landscape of MDS and its impact on disease diagnosis, prognosis, and treatment decisions. The book continues by profiling different prognostic models of MDS and concludes with a thorough review of treatment algorithms for lower and higher-risk MDS, as well as the use of hematopoietic stem cell transplant to combat the disease.Written by experts in the field, Diagnosis and Management of Myelodysplastic Syndromes: A Clinical Guide is a valuable resource for clinicians, practitioners, and researchers who are interested in MDS. The text also features over 100 illustrations, photographs, and tables.
Vertaile hintoja
Diagnosis and Management of Myelodysplastic Syndromes

Diagnosis and Management of Myelodysplastic Syndromes

Springer Nature Switzerland AG
2021
nidottu
Myelodysplastic syndromes (MDS) are a group of clonal disorders characterized by pancytopenias and the risk of progression to acute myeloid leukemia. The diagnosis of MDS can be challenging, while the outcomes of MDS patients vary widely. This book provides a concise yet comprehensive overview of MDS.The book begins by reviewing the diagnostic workup of MDS, with a specific focus on the 2016 WHO criteria for MDS diagnosis, and the biology and pathophysiology of the disease. The text then presents the molecular landscape of MDS and its impact on disease diagnosis, prognosis, and treatment decisions. The book continues by profiling different prognostic models of MDS and concludes with a thorough review of treatment algorithms for lower and higher-risk MDS, as well as the use of hematopoietic stem cell transplant to combat the disease.Written by experts in the field, Diagnosis and Management of Myelodysplastic Syndromes: A Clinical Guide is a valuable resource for clinicians, practitioners, and researchers who are interested in MDS. The text also features over 100 illustrations, photographs, and tables.
Vertaile hintoja
Classifications and prognosis of myelodysplastic syndromes

Classifications and prognosis of myelodysplastic syndromes

Wijden El Borgi; Rania Boughzala

Our Knowledge Publishing
2023
pokkari
Myelodysplastic syndromes (MDS) form a heterogeneous group of clonal hemopathies that are on the increase due to an aging population. Study objective: to establish the FAB and WHO 2008 classifications, IPSS and WPSS prognostic scores of 85 MDS diagnosed at our center over a 5-year period. The mean age of patients was 63.8 years. Anemia was present in 85% of patients. Dysplasia of the 3 erythroblastic, granular and megakaryocytic lineages was found in 75%, 85% and 68% of cases respectively. Cytogenetic abnormalities were present in 33% of cases, with 5q- abnormalities predominating. Refractory anemias and refractory cytopenias with multilineage dysplasia were most frequently observed. Low- and intermediate-risk groups1 according to the IPSS and low- and high-risk groups according to the WPSS were the most represented. Median survival was significantly different between prognostic groups. Transformation to acute myeloid leukemia occurred in 32% of cases. The risk of transformation was significantly different between MDS prognostic groups.
Vertaile hintoja
12